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Abstract
Several groups have generated programmable transcription factors based on the versatile Cas9 
protein, yet their relative potency and effectiveness across various cell types and species remain 
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unexplored. Here, we compare Cas9 activator systems and examine their ability to induce robust 
gene expression in several human, mouse, and fly cell lines. We also explore the potential for 
improved activation through the combination of the most potent activator systems and assess the 
role of cooperativity in maximizing gene expression.
 Introduction
Cas9 is an RNA-guided endonuclease that can be directed to cut a selected site1,2. This 
process requires complementarity between the Cas9-associated guide RNA (gRNA) and the 
target site, along with the presence of a short protospacer adjacent motif3,4,5,6. Early efforts 
at engineering the Cas9 protein uncovered several residues involved in DNA catalysis that, 
when mutated, generate forms of the protein that are still capable of DNA binding but lack 
detectable nuclease activity4,7,8. These nuclease-null, or “dead,” Cas9 (dCas9) variants can 
then be fused to effector domains, allowing users to precisely direct a given functional 
activity to any arbitrary locus within the genome7,9,10,11. Recently, several groups have 
generated systems to endow dCas9 with the ability to activate gene expression, with dCas9-
VP64 representing the first activator and the standard against which subsequent “second-
generation” activators are typically compared12,13,14,15,16,17,18,19. Due to differences in the 
cellular context in which the various second-generation activators were tested and non-
uniformity with regard to the particular target genes, guide RNA, transfection conditions, 
and time to analysis of gene induction, it remains ambiguous which system is the most 
potent and whether any individual system possesses unique properties not displayed by the 
others20,21,22. Here, we conduct a survey of the various second-generation activators, 
identifying the most potent systems, which we rigorously characterize across a plethora of 
target genes and species. These data confer much needed guidance to those wishing to adopt 
dCas9 activator technology and provide the community with an extensive set of validated 
reagents to aid the adoption of these tools within labs without previous experience.
 Results
The number of second-generation dCas9 activators is too large to be systematically tested 
across a large panel of target genes and cell lines. Accordingly, we first performed a series of 
pilot experiments within human embryonic kidney (HEK) 293T cells to compare 
representative examples of all published dCas9 activators (Fig 1a). As expected, for the two 
target genes tested, the majority of second-generation systems show improved levels of 
activation as compared to dCas9-VP64, with three activators in particular - VPR, SAM, and 
Suntag - appearing to be the most potent (Fig 1b and activators described in detail in 
Supplementary Note 1)12,13,15,16. Based on these initial data, we decided to focus our 
efforts on VPR, SAM, and Suntag.
When compared across a panel of coding and non-coding genes, VPR, SAM, and Suntag 
demonstrate the ability to induce potent gene expression. At times, this activation reached 
levels several orders of magnitude higher than the first-generation dCas9-VP64 activator 
(Fig. 2a and Supplementary Fig. 1). SAM was the most consistent in delivering high levels 
of gene induction, although it always remained within five-fold of either Suntag or VPR, 
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neither of which was generally superior to the other (Fig. 2a). Previously, a negative 
correlation between the basal expression state of a given gene and the fold change in gene 
expression upon targeted upregulation by dCas9-based activators was reported12,13. In other 
words, lowly expressed genes tend to have a higher fold induction than highly expressed 
genes. We find that this phenomena is a general principle for each of the tested synthetic 
activators, which suggests that these systems are only capable of inducing gene expression 
to some static upper limit, dependent upon the activator architecture employed 
(Supplementary Figure 2).
One of the benefits of dCas9-based transcriptional effectors over other synthetic 
transcription factors is the ease by which multiple loci can be upregulated, only requiring the 
provision of an extra gRNA for each additional locus one desires to activate. Previous work 
has shown a general decrease in gene activation upon multiplexing, but whether this is true 
of all systems is unknown12,19. To address this question, we performed a series of multiplex 
activation experiments (Supplementary Fig. 3). When activating three genes at once 
between VPR, SAM, and Suntag, no system appeared superior to the others with all showing 
similar levels of activation, within an order of magnitude of each other for the majority of 
target genes. This is a somewhat surprising finding given that SAM and Suntag are believed 
to require the assembly of large multimember protein complexes in order to generate a 
highly competent activator. To further investigate the limitations of multiplexing, we 
simultaneously directed each of the systems to six target genes at once. Even within this 
more complex activation scheme all systems showed similar levels of relative gene 
activation, and in doing so highlight the robustness of these tools to actuate complex 
transcriptional regulation (Fig 2b). Of note, we observe within our control samples inherent 
variation in the level of basal gene expression upon which we base our calculation of relative 
fold induction. We are therefore unable to make comparisons with regard to the absolute 
amount of activation a given system can perform when targeted to a single gene versus 
multiple genes by comparing expression data across experiments.
An important concern for any Cas9-based technology is the specificity of the desired effect. 
It has been demonstrated that Cas9 binds promiscuously throughout the genome23. This 
effect could potentially result in aberrant transcription for Cas9-activators if they were to 
bind to the wrong promoter. To test the specificity of each activator, we performed whole 
RNA-seq on samples with each of our activators targeting HBG1 (Figure 3). We found that 
the correlation in gene expression between each activator and our control sample was very 
similar to the correlation between biological replicates in our dataset (R ~ 0.98 in each case), 
indicating that gene expression is not broadly affected by the presence of any activator 
(Figure 3a). Disregarding noise from genes with low baseline expression (<0.1 TPM), 
HBG1 was the most highly upregulated gene in each sample except for VP64, indicating 
that the activators are highly specific (Figure 3b).
To further explore the generality of the trends we observed within HEK293T cells, we 
targeted a smaller subset of genes within other biomedically relevant human cell lines (Hela, 
U-2 OS, and MCF7). While Hela cells demonstrated a similar trend of SAM leading to more 
potent activation, U-2 OS and MCF7 cells showed a deviation from this trend with Suntag 
and VPR being the more potent activators (Fig 4a and Supplementary Fig 4a). The 
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biological basis for these cell-line specific differences remains to be determined and is not 
likely due to differences in basal expression state given that HBG1 and TTN are expressed at 
a similarly low basal state across the tested cell lines (data not shown).
Because human cell lines represent only a single context within which dCas9-based 
activators might be employed, we performed a series of experiments within mouse N2A and 
3T3 cells as well as Drosophila S2R+ cells13. As a whole, all second-generation activators 
showed improved activity as compared to the dCas9-VP64 standard. Within mouse and 
Drosophila cells, VPR, SAM, and Suntag showed similar levels of gene induction (within 
five-fold of each other), with the most potent activator changing depending on the target 
analyzed (Fig 4b and Supplementary Fig 4b).
Given that VPR, SAM, and Suntag represent divergent approaches to Cas9 activator design, 
we sought to determine if any of the activator components could be combined to generate a 
hybrid activator with increased potency. First, we naively combined each of the systems 
(Supplementary Fig. 5). For example, we used the Suntag dCas9 component and the SAM-
modified gRNA to simultaneously recruit both scFv-VP64 to the end of dCas9 and p65-hsf1 
to the gRNA. In addition, we tested if systems such as SAM or Suntag that rely on recruiting 
several copies of their activator p65-hsf1 or VP64, respectively might be enhanced by 
nucleating a different activator such as VPR (Supplementary Fig. 6). Finally, we 
investigated if the MS2 hairpins utilized within the SAM system to recruit the MS2 binding 
protein-p65-hsf1 activator component might be enhanced by combining them in part or in 
whole with the scaffold method of MS2 binding protein mediated activator recruitment 
(Supplementary Fig. 7). Towards this goal a hybrid SAM+Scaffold gRNA was generated 
along with a series of chimeras containing select portions of each system combined together. 
Despite our exhaustive attempts, there was no combination of dCas9 activators, secondary 
effector component alteration, or gRNA modification that could lead to a chimeric system 
with enhanced transcriptional regulatory capacity for either single or multiplex gene 
induction.
Previous work with the first-generation dCas9-VP64 activator uncovered a role for 
cooperativity in enabling synergistic increases in gene activation7,10,11,24,25. Whether this 
observation is also true for the significantly more potent second-generation activators 
remains unexplored. It is likely that the extendibility of these newer systems may be limited 
from further increasing gene expression due to insufficient host resources (such as local 
RNA polymerase concentrations near a given locus)26. To study the effects of recruiting 
multiple dCas9 activator complexes to the same locus, we generated three gRNAs against a 
lowly, intermediately, and highly expressed gene target (ASCL1, NEUROD1, and CXCR4 
respectively) within HEK293T cells and transfected each of the gRNAs alone or all the 
gRNAs against a given target gene at once. Simultaneous targeting of the same gene with 
multiple gRNAs led to additive or greater levels of gene activation (Fig. 4c).
 Discussion
Cas9-based activation represents a powerful method to study gain-of-function phenomena on 
genomic scales and has already been used to uncover mechanisms of toxin-mediated cell 
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death and resistance of tumor cells to targeted therapy.12,15 While it is tempting for those 
analyzing the initial Cas9 activator publications to make cross-study comparisons, these 
types of analysis are fraught with confounding variables, such as differences in the cell line 
used, gRNA selected, amount of Cas9 complex transfected, and time until RNA extraction. 
In addition, often overlooked variation in the basal expression level of some of the more 
lowly expressed target genes can lead to large differences in the perceived performance of 
one system over another. Within our own data, there are instances where the absolute level 
of target gene activation differs due to these changes, despite these experiments being 
performed under similar conditions (Fig 1 and Supplementary Fig 1). This source of 
variation emphasizes the need for comparisons across activators to be performed within a 
single experiment if users want to make statements with regard to absolute levels of gene 
induction. In contrast, for cases where understanding a relative difference in performance is 
the primary goal, differences in basal expression state will no longer play a role as each 
activator is compared to each other thus eliminating variance due to basal expression state.
Our results demonstrate that, across a range of target genes and cellular environments, the 
VPR, SAM, and Suntag systems are consistently superior to the previous VP64 standard. In 
addition, while SAM shows a trend for more potent activation in some contexts, VPR, SAM, 
and Suntag generally fall within an order of magnitude of each other with regard to fold 
increase in gene expression. It is additionally comforting that each activator was similarly 
specific. This suggests that constraints outside of the ability to induce gene expression or 
specificity, such as ease of delivery, familiarity with the system, and access to the necessary 
reagents, may be more practical concerns to consider27.
It is assuring that the second-generation activators show robust activation even when 
employed in organisms such as Drosophila that are very distantly related to the human cell 
lines in which these tools were developed. The demonstrated portability of these dCas9 
activators across disparate model systems and species suggests that they hold potential as 
universal genetic tools. It is likely that these systems will prove effective across a wide range 
of scientifically interesting organisms with minimal additional engineering.
Our attempts to build an improved chimeric activator by fusing elements from VPR, SAM, 
and Suntag were unsuccessful (Supplementary Figs. 5-7). This is particularly unexpected 
given the drastically different ways in which the systems generate a functional 
activator12–16. It is difficult to disentangle issues such as steric interference between 
neighboring activator elements from the possibility that each of these systems28, while 
different, may be interacting with a similar subset of the transcriptional regulatory 
machinery29,30. Future efforts to improve dCas9-based activators may benefit from 
exploring other unique architectures or novel activation domains, along with examining the 
use of epigenetic modifiers to provide complementary mechanisms to further enhance 
activation18,31.
While we did not perform experiments to explicitly address potential differences in gRNA 
binding site preferences between VPR, SAM, and Suntag, it is telling that for experiments 
where several gRNAs against the same gene were examined, the activators show the same 
gRNAs as being either the most potent or the least potent (Fig. 4c). These data suggest that 
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the rules governing activator placement within a given promoter region are shared. It will be 
interesting to characterize the properties shared by highly potent gRNAs to help distinguish 
effects of distance from the transcriptional start site from features such as gRNA sequence 
composition and stability.12,15,32,33,23 In addition, the fact that we are able to achieve 
increased levels of programmable gene induction by employing multiple gRNAs against a 
single target gene suggests that none of the current Cas9 activators have yet to achieve 
“maximal activation”. Since if they were, each activator would not have been aided by the 
use of multiple guides. These results suggest that continued improvements to Cas9 activators 
are still possible and should aid in generating a more reliable tool for performing systematic 
genome-wide screens.
Although not highlighted in any of the original studies for VPR, SAM, or Suntag, our results 
suggest that the combination of multiple gRNAs represents a viable strategy to enhance gene 
expression in cases where maximal induction is desired. This strategy may be most valuable 
for highly expressed genes, which are generally recalcitrant to large amounts of 
overexpression from the native locus12,13. It could also be used to assure that all genes are 
consistently upregulated given that even for easily upregulated genes there can be over a 
hundred-fold difference in potency between various gRNAs (Fig. 4c).
 Materials and methods
 Vector design and construction
Vectors used and guide scaffolds will be deposited to Addgene
dCas9-VP64 (Addgene #47319), dCas9-VPR (Addgene #63798), dCas9-VP64 (for SAM 
activation Addgene # 61425), MCP-p65-hsf1 (Addgene #61426), dCas9-10xGCN4 
(Addgene #60903), scFv-VP64 (Addgene #60904), dCas9-p300core (Addgene #61357), 
dCas9-VP160 (Addgene #48225), Cas9-m4 (Addgene #47316) and MCP-VP647 were 
previously described.
For all systems tested the original vectors deposited to Addgene were employed allowing us 
to use the presumably optimal expression vector decided upon by the various depositing 
laboratories. dCas9-VP64, dCas9-VPR, dCas9-p300, dCas9-VP160, and dCas9-m4 
constructs were all driven under CMV promoters. dCas9-VP64 (for SAM activation) and 
MCP-p65-hsf1 used EF1alpha promoters and dCas9-10xGCN4 and scFv-VP64 used SV40 
promoters.
Gibson cloning was utilized to make all variants. For SAM and Scaffold gRNA variants, 
gene blocks were used (Integrated DNA Technologies). See Supplementary Note 2 for full 
sequence information.
All dCas9 activator components were cloned into a Drosophila pActin vector using Gibson 
assembly,34,35 adding a Kozak sequence (GCCACC) immediately upstream of the start 
codon.
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To generate Drosophila MS2-containing sgRNA expression vectors for SAM and Scaffold, 
the pCFD3 plasmid was modified via Gibson assembly to include the indicated sgRNA 
tails.36 For all sgRNA plasmids guide oligos were cloned using a BbsI digest.36
 Mammalian cell culture
All human and mouse cell lines were maintained in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% FBS and penicillin-streptomycin (all from ThermoFisher) 
in an incubator set at 5% CO2 and 37° celsius. MCF7 (gift of J. Lee, Cold Spring Harbor, 
Cold Spring Harbor, NY) media was supplemented with 0.01mg/ml human recombinant 
insulin (EMD Millipore). HEK293Ts, Helas (both gifts of P. Mali, UCSD, San Diego, CA), 
U-2 OS (ATCC HTB-96), MCF7s, N2As (ATCC CCL-131), and NIH-3T3s (gift of S. 
Shipman, Harvard Medical School, Boston, MA) were seeded into 24-well plates for 
transfection.
Cell lines were not tested for authenticity and were tested yearly for mycoplasma.
 Mammalian transfections
DNA was aliquoted into individual tubes prior to transfection. 25ng of plasmid DNA 
containing the Cas9 component and 10ng of plasmid DNA with the guide was transfected 
into each well. For activators requiring a second component (Suntag, SAM, Scaffold), 100ng 
of plasmid DNA containing that component was also transfected. For all the other activators, 
100ng of an empty vector (Puc19) was substituted for the secondary component in order to 
ensure equal amounts of DNA were transfected. For experiments involving multiple guides 
targeted towards one gene, the amount of gRNA plasmid per transfection was scaled so that 
the total plasmid gRNA in each well was 10ng. For example, for three gRNAs activating one 
gene, 3.33ng of each guide was transfected. In experiments involving multiple guides 
targeted towards different genes, 10ng of gRNA plasmid DNA was transfected per target. 
For all gRNA spacer sequences, please see Supplementary Table 1.
293T cells were transfected with Lipofectamine 2000 (ThermoFisher) using the following 
protocol. For each transfection, a stock solution of 50 μl of Opti-Mem (ThermoFisher) and 2 
μl of Lipofectamine 2000 per transfection was made. The solution was then vortexed and 
incubated for five minutes. The Opti-mem/Lipofectamine solution was then added to the 
individual aliquots of DNA, vortexed and spun in a centrifuge at 100RPM for 1 minute. The 
DNA was then incubated for 30 minutes before being added to the cells.
All other cell lines were transfected with Lipofectamine 3000 (ThermoFisher) using the 
following protocol. 25 μl of Opti-MEM was added to each DNA aliquot along with 1 μl 
P3000 reagent per transfection. Master mixes of Opti-MEM and Lipofectamine 3000 were 
prepared with 25 μl of Opti-Mem and 1 μl or 0.5 μl of Lipofectamine 3000 per transfection. 
MCF7s, N2As, and U-2 OSes were transfected using 1 μl of P3000 reagent and 0.5 μl of 
Lipofectamine 3000 reagent per transfection. N2As and NIH-3T3s were transfected with 1 
μl of P3000 reagent and 1 μl of Lipofectamine 3000 reagent per transfection. The solutions 
were vortexed and incubated separately for five minutes before 25 μl of the Lipofectamine 
3000/Opti-Mem mix per transfection were added to the DNA aliquots. These new solutions 
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were then vortexed, centrifuged at 100RPM for 1 minute, incubated for 30 minutes and then 
added to the cells.
To avoid excess toxicity to the cells, media was changed after 24 hours for the 293T, N2A 
and NIH-3T3 cells. Otherwise, media was changed after 4 hours.
 RNA extraction and qPCR analysis for mammalian cell lines
Cells were harvested for RNA 48 hours post-transfection. RNA was extracted using the 
RNeasy Plus Mini Kit (Qiagen). cDNA was synthesized using the iScript cDNA synthesis 
kit (Bio-Rad) using 500ng of RNA per cDNA reaction. qPCR reactions were prepared using 
the KAPA SYBR Fast Universal 2x quantitative PCR kit using 0.5 μl of cDNA per reaction 
in a 20 μl total reaction volume. Gene expression was normalized to the expression of the 
gene ACTB for human cell lines and the mouse ortholog (actb) for mouse cell lines as an 
internal housekeeping gene. Cycling conditions were as follows: 95° for 1 minute, 95° for 
10 seconds and 60° for 30 seconds. The latter two steps cycled for 50 repeats with plate 
reads taken after the 60° step. If a sample failed to amplify after 50 cycles, an arbitrary Cq 
count of 50 was substituted (this occurred in a single instance). For qPCR primer sequences, 
please see Supplementary Table 2.
 RNA-seq analysis
For each sample, 100 ng of total RNA was DNase treated with Turbo DNase (ThermoFisher 
Scientific) at 37C for 30 minutes and then cleaned up with Agenocourt RNAClean XP Beads 
(Beckman Coulter). The RNA samples were polyA selected using Dynabeads mRNA Direct 
Purification Kit (ThermoFisher Scientific). RNA-Seq Libraries were constructed using 
Maxima H Minus First Strand Synthesis Kit (ThermoFisher Scientific) with random 
hexamers and then the NEBNext mRNA Second Strand Synthesis Module (New England 
Biolabs). The resulting cDNA was cleaned up with Agencourt AMPure XP Beads (Beckman 
Coulter) and then went into the Nextera XT DNA Library Prep Kit (Illumina). Final 
Libraries were once again cleaned with Agencourt AMPure XP Beads and analyzed on a 
BioAnalyzer using a High Sensitivity DNA Analysis Kit (Agilent). Libraries were quantified 
using a Qubit dsDNA HS Assay Kit (ThermoFisher Scientific), pooled, and and run on one 
lane of an Illumina HiSeq 2500 using 2×25 bp paired end reads. Reads were aligned to the 
hg19 UCSC Known Genes annotations using RSEM v1.2.1 and were analyzed in Python37 
Histograms showing the distribution of fold-changes in gene expression (activator/guide 
control). Genes were filtered to include only those with TPM > 0.000001. Arrows indicate 
fold change of HBG1 for the indicated activator. Average of two biological replicates shown. 
Differential gene-expression analysis was done using the Voom38 and Limma39 packages in 
R for all genes with ≥0.000001. TPM mapped reads in each replicate, where differential 
expression was defined by a Benjamini-Hochberg adjusted P value of <0.05 and fold change 
of >10 or <0.1.”
 Drosophila melanogaster transfections
S2R+ cells were transfected in 24-well plates using Effectene reagent (Qiagen). Each well 
was transfected with 50 ng of dCas9 component, 200 ng of any additional activator 
component, and 15 ng of sgRNA, and empty vector was used to equalize the total amount of 
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DNA in each transfection to 265 ng. For multiplex reactions, 15 ng of each sgRNA were 
added.
Total RNA was collected three days after transfection, and qPCR was conducted as 
previously described.40
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Initial tests of all second-generation activators on endogenous genes in HEK293T cells
(a)dCas9-VP64 and dCas9-VPR both work via activation domains fused to the C-terminus 
of Cas9. SAM uses dCas9-VP64, but recruits more activation domains to the gRNA. 
Scaffold recruits multiple copies of VP64 to the gRNA. Suntag uses single chain antibodies 
to recruit multiple copies of VP64 to the peptide tail. P300 uses the catalytic core of the 
epigenetic modifier fused to dCas9 to modify the chromatin around the promoter to drive 
transcription. VP160 is the direct fusion of 10 repeats of VP16 protein to dCas9 instead of 
the usual four that makes up VP64. VP64-dCas9-BFP-VP64 drives transcription via the 
fusion of VP64 to both the N and C-termini of Cas9 (b)Data indicate the mean + s.e.m (n = 
2 independent transfections).
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Figure 2. Activation of endogenous genes in HEK 293T cells
(a) RNA expression analysis on 6 endogenous human genes. Data indicate the mean + s.e.m 
(n = 2 independent transfections). (b) Multiplexed activation of six endogenous human 
genes. Data indicate the mean + s.e.m (n = 2 independent transfections).
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Figure 3. Evaluation of activator specificity by RNA sequencing
(a) Gene expression levels (log2TPM, Transcripts Per Million) in cells transfected with the 
indicated activator targeting HBG1 (y axis) vs. expression in cells transfected with guide 
RNA only (x axis). R indicates Pearson's correlation coefficient, calculated for log-
transformed values on all genes except HBG1. Genes with 0 TPM in both replicates of either 
the activator or control were excluded before log transformation. Average of two biological 
replicates shown. (b) Histograms showing the distribution of fold-changes in gene 
expression (activator/guide control). Genes were filtered to include only those with TPM > 
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0.1. Bottom panel is zoomed in on the range 2-400. In both panels arrows indicate fold-
change of HBG1 for the indicated activator. Average of two biological replicates shown.
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Figure 4. Activation of endogenous genes in alternative human, mouse and fly cell lines and 
effects of multiple guides
(a) Activation of endogenous genes in Hela, U-2 OS and MCF7 cells. Data indicate the 
mean + s.e.m (n = 2 independent transfections). (b) Activation of endogenous genes in 
mouse and fly. Data indicate the mean + s.e.m (n = 2 independent transfections) (c) Samples 
were transfected with the indicated guide or mixtures of guides. Theoretical sum indicates 
sum of the relative RNA expression for each activator of the individual gRNAs. Data 
indicate mean +S.E.M. (n = 2 independent transfections)
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